HAEMONETICS CORP HAE

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived NYSE

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. When used in this report, the terms "we," "us," "our," "Haemonetics" and the "Company" mean Haemonetics Corporation.

We view our operations and manage our business in three principal reporting segments: Plasma, Blood Center and Hospital. For that purpose, "Plasma" includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. "Blood Center" includes blood collection and processing devices and disposables for plasma, red cells and platelets. "Hospital" is comprised of Interventional Technologies, which includes Vascular Closure, Sensor-Guided Technologies and Esophageal Protection product lines, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. Financial information concerning these segments is provided in Note 18, Segment and Enterprise-Wide Information, within the consolidated financial statements in Item 8 of this Annual Report on Form 10-K.

Last close 118.51 2026-10-23
Market cap $5.39B 2026-06-27 share count
52-week range 48.98 - 123.77

Valuation FY2025 figures against the last close

P/S4.0x
P/E57.8x
P/FCF20.7x
EV/EBITDA29.2x
Dividend yield—
Diluted EPS2.05

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Europe
  • Rest of Asia
  • Japan
  • Other
Revenue by geography, 5 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 982.2M (73.6%) 74% United States Europe, FY2025: 185M (13.9%) 14% Europe Rest of Asia, FY2025: 87.2M (6.5%) 7% Japan, FY2025: 68.2M (5.1%) 5% Japan Other, FY2025: 11.4M (0.9%) FY2024 United States, FY2024: 1B (74.3%) 74% Europe, FY2024: 175.7M (12.9%) 13% Rest of Asia, FY2024: 92.3M (6.8%) 7% Japan, FY2024: 62.4M (4.6%) 5% Other, FY2024: 19.5M (1.4%) FY2023 United States, FY2023: 970M (74.1%) 74% Europe, FY2023: 160.1M (12.2%) 12% Rest of Asia, FY2023: 107.5M (8.2%) 8% Japan, FY2023: 58.1M (4.4%) 4% Other, FY2023: 13.3M (1.0%)
Region FY2025FY2024FY2023
United States $982.2M $1.01B $970.0M
Europe $185.0M $175.7M $160.1M
Rest of Asia $87.2M $92.3M $107.5M
Japan $68.2M $62.4M $58.1M
Other $11.4M $19.5M $13.3M

As the company reported it, from the “SEGMENT AND ENTERPRISE-WIDE INFORMATION - Segment Information By Geographic Region (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $1.33B$1.36B$1.31B$1.17B$993.2M$870.5M$988.5M$967.6M$903.9M$886.1M
Cost of revenue $546.4M$611.9M$617.5M$553.6M$487.7M$472.6M$504.0M$550.0M$492.0M$507.6M
Gross profit $787.6M$749.0M$691.5M$615.1M$505.5M$397.8M$484.5M$417.5M$411.9M$378.5M
R&D $59.8M$62.7M$54.4M$50.1M$46.8M$32.9M$30.9M$35.7M$39.2M$37.6M
SG&A $442.4M$436.8M$429.8M$376.7M$340.1M$275.2M$282.0M$273.5M$316.5M$301.7M
Total operating expenses $630.9M$527.1M$526.7M$459.1M$424.8M$308.1M$381.2M$334.0M$355.8M$397.9M
Operating income $156.7M$221.8M$164.9M$156.0M$80.8M$89.7M$103.4M$83.5M$56.2M-$19.4M
Pre-tax income $128.0M$212.1M$151.9M$141.4M$63.6M$72.9M$87.2M$73.6M$59.6M-$27.5M
Income tax $30.7M$44.4M$34.3M$26.0M$20.3M$6.6M$10.6M$18.6M$14.1M$1.2M
Net income $97.3K$167.7K$117.6M$115.4M$43.4M$79.5M$76.5M$55.0M$45.6M-$26.3M
EPS, basic 2.063.332.322.270.851.571.511.070.86-0.51
EPS, diluted 2.053.312.292.240.841.551.481.040.85-0.51
Shares, diluted (wtd. avg.) 47.4M50.7M51.4M51.4M51.4M51.3M51.8M52.9M53.5M51.5M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $245.4M$306.8M$178.8M$284.5M$259.5M$192.3M$137.3M$169.4M$180.2M$139.6M
Receivables $216.9M$202.7M$206.6M$179.1M$159.4M$127.6M$165.2M$185.0M$151.2M$152.7M
Inventory $306.4M$365.1M$317.2M$259.4M$293.0M$322.6M$270.3M$194.3M$160.8M$176.9M
Total current assets $834.9M$935.0M$768.9M$769.7M$756.0M$693.5M$603.6M$576.1M$521.2M$510.0M
Property, plant and equipment $305.8M$284.1M$311.4M$310.9M$258.5M$217.6M$253.4M$344.0M$332.2M$323.9M
Goodwill $656.4M$604.3M$565.1M$466.2M$467.3M$466.4M$210.7M$210.8M$211.4M$210.8M
Other intangibles $447.7M$455.7M$406.1M$275.8M$310.3M$365.5M$133.1M$127.7M$156.6M$177.5M
Total assets $2.40B$2.45B$2.20B$1.93B$1.86B$1.82B$1.27B$1.27B$1.24B$1.24B
Accounts payable $51.1M$67.0M$73.4M$63.9M$58.4M$50.3M$50.7M$63.4M$55.3M$43.0M
Short-term debt $5.0M$303.6M$10.2M$11.8M$214.1M$17.0M$77.0M$27.7M$194.3M$61.0M
Total current liabilities $282.6M$578.1M$300.4M$251.8M$442.3M$253.5M$274.8M$235.8M$384.7M$211.2M
Long-term debt $1.22B$921.2M$797.6M$754.1M$559.4M$690.6M$305.5M$322.5M$59.4M$253.6M
Retained earnings $279.3M$352.2M$360.5M$253.2M$202.4M$158.0M$78.5M$161.4M$266.9M$289.9M
Total equity $796.3M$820.8M$960.0M$818.0M$749.4M$731.7M$587.1M$667.9M$752.4M$739.6M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $293.2M$181.7M$181.8M$273.1M$172.3M$108.8M$158.2M$159.3M$220.3M$159.7M
Depreciation and amortisation $61.2M$60.0M$55.8M$51.2M$44.4M$43.1M$76.6M$76.8M$57.7M$66.5M
Stock-based compensation $33.8M$29.6M$28.3M$25.6M$24.4M$25.5M$20.5M$17.2M$13.0M$9.2M
Capital expenditure $32.8M$39.3M$38.1M$191.3M$96.5M$37.0M$48.8M$119.0M$74.8M$76.1M
Investing cash flow -$179.5M-$161.9M-$322.4M-$143.8M-$86.3M-$425.4M-$57.2M-$116.1M-$63.0M-$73.3M
Financing cash flow -$178.5M$108.8M$38.2M-$100.4M-$15.7M$367.5M-$131.2M-$50.6M-$120.6M-$60.4M
Buybacks $175.0M$225.0M$0$75.0M$0$0$175.0M$160.0M$100.0M$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000313143-26-000074.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -500M 0 500M 1B 1.5B Revenue, FY2016: 886.1M Gross profit, FY2016: 378.5M Net income, FY2016: -26.3M Revenue, FY2017: 903.9M Gross profit, FY2017: 411.9M Net income, FY2017: 45.6M Revenue, FY2018: 967.6M Gross profit, FY2018: 417.5M Net income, FY2018: 55M Revenue, FY2019: 988.5M Gross profit, FY2019: 484.5M Net income, FY2019: 76.5M Revenue, FY2020: 870.5M Gross profit, FY2020: 397.8M Net income, FY2020: 79.5M Revenue, FY2021: 993.2M Gross profit, FY2021: 505.5M Net income, FY2021: 43.4M Revenue, FY2022: 1.2B Gross profit, FY2022: 615.1M Net income, FY2022: 115.4M Revenue, FY2023: 1.3B Gross profit, FY2023: 691.5M Net income, FY2023: 117.6M Revenue, FY2024: 1.4B Gross profit, FY2024: 749M Net income, FY2024: 167.7K Revenue, FY2025: 1.3B Gross profit, FY2025: 787.6M Net income, FY2025: 97.3K FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $886.1M $903.9M $967.6M $988.5M $870.5M $993.2M $1.17B $1.31B $1.36B $1.33B
Gross profit $378.5M $411.9M $417.5M $484.5M $397.8M $505.5M $615.1M $691.5M $749.0M $787.6M
Net income -$26.3M $45.6M $55.0M $76.5M $79.5M $43.4M $115.4M $117.6M $167.7K $97.3K

Recent filings and events

  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%